DHFR

Proguanil hydrochloride is a dihydrofolate reductase (DHFR) inhibitor primarily utilized in antimalarial research. It is metabolized into the active compound Cycloguanil, which demonstrates significant efficacy against Plasmodium species. This reagent is essential for studies focused on antimalarial drug development and exploration of DHFR pathways in cellular metabolism.

N-Didesmethyladitoprim is a metabolite of the selective bacterial dihydrofolate reductase (DHFR) inhibitor, Aditoprime. This compound effectively inhibits the conversion of dihydrofolic acid to tetrahydrofolic acid, demonstrating an IC50 of 47 nM against E. coli and 520 nM against L. casei DHFR. N-Didesmethyladitoprim exhibits broad-spectrum antibacterial activity and possesses favorable pharmacokinetic properties, making it a valuable tool for research in antimicrobial mechanisms and DHFR inhibition studies.

NSC309401 is a potent inhibitor of dihydrofolate reductase (DHFR) from E. coli, exhibiting an IC50 value of 189 nM and a KD of 14.57 nM. This compound is essential for studying folate metabolism and can be utilized in research applications related to antimicrobial drug development and cancer therapeutics. Its specificity for DHFR makes it a valuable tool for elucidating the biochemical pathways influenced by folate synthesis.

DHFR-IN-10 is a potent inhibitor of dihydrofolate reductase (DHFR), exhibiting an IC50 of 4.21 μM against M. tuberculosis DHFR. This compound demonstrates significant antituberculosis efficacy, making it a valuable tool in research focused on combating tuberculosis and studying DHFR-related pathways. Its effectiveness positions DHFR-IN-10 as a potential lead candidate for further development in anti-tubercular drug discovery.

NSC309401 dihydrochloride is a selective inhibitor of dihydrofolate reductase (DHFR) from Escherichia coli, exhibiting an IC50 of 189 nM and a KD of 14.57 nM. This compound is primarily utilized in studies focused on microbial metabolism and antibiotic resistance. Its potent inhibition of DHFR makes it a valuable tool in researching folate biosynthesis pathways and developing novel therapeutic agents.

PROTAC eDHFR Degrader-1 is a proteolysis-targeting chimera (PROTAC) that specifically targets eDHFR for ubiquitin-mediated degradation. This compound effectively degrades eDHFR-YFP and various protein of interest (POI), including yellow fluorescent protein (YFP) and luciferase. Its application in research can facilitate the study of protein function and dynamics through targeted protein degradation, providing insights into cellular processes and potential therapeutic pathways.

Proguanil is a potent dihydrofolate reductase (DHFR) inhibitor, primarily utilized in antimalarial research. Upon administration, it is metabolized to Cycloguanil, its active form, enhancing its efficacy against Plasmodium species. This compound is essential for studying the biochemical pathways of folate metabolism and developing therapeutic strategies against malaria.